NVS - Novartis Corporation Stock Quotes

Novartis AG (NVS) manages a global medical holding. This chart reflects a price trend at the 160.21 level, while geopolitical risks create threats regarding the privatization of drug formulas. The company attracts leading scientists through the academic environment and generous compensation. The business relies on advanced gene therapy methods, leaving simple generic drug copies outside its structure.

Market Chart: Novartis AG (NVS) for 07/04/2022 - 11/14/2026

Financial and market metric breakdowns for Novartis Corporation (NVS)

- stock value and consensus price forecast:

Price Chart Novartis AG|NVS - Broker Consensus Forecast

- market capitalization statistics:

Market Valuation Novartis Corporation|NVS - Total Company Value

- issuer book value statistics:

Net Assets per Single Share Novartis|NVS - Book Valuation of Business|Market Value to Book Value Ratio novartis.com|NVS - Total Asset Value of Company

- debt obligations and liquidity statistics:

- company profitability and valuation multiples indicators:

NVS - Net Profit|Future Profit Novartis AG|NVS - Company Value to Net Income|Forward P/E Multiple Novartis|NVS - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Novartis Corporation|NVS - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Novartis|NVS - Earnings per share for the last twelve months|Quarterly EPS earnings growth novartis.com|NVS - Earnings per share growth this year|Earnings growth forecast for next year Novartis AG

- revenue and sales proceeds data:

NVS - Company Gross Revenue|Company Projected Revenue Novartis AG|NVS - Market Cap to Revenue Ratio|Forward P/S Multiple Novartis Corporation

Comprehensive company analysis:NVS Novartis AG

Price captures the equilibrium point between supply and demand, establishing the base for calculating future return on capital. This indicator reflects the market valuation of investor expectations regarding the business's cash flows. The market value dynamics of Novartis AG (NVS) demonstrate how the market capitalizes patents and breakthroughs in radioligand therapy. Analyzing the price trajectory allows for a comparison of the current valuation against R&D expenditures, which is critical for assessing the long-term investment potential of the Swiss behemoth.

Direct competitors